83 related articles for article (PubMed ID: 31508747)
21. Rural-Urban Differences in Prostate-Specific Antigen (PSA) Screening and Its Outcomes in New Zealand.
Obertová Z; Hodgson F; Scott-Jones J; Brown C; Lawrenson R
J Rural Health; 2016; 32(1):56-62. PubMed ID: 26174590
[TBL] [Abstract][Full Text] [Related]
22. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
23. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
Yamamoto T; Musunuru HB; Vesprini D; Zhang L; Ghanem G; Loblaw A; Klotz L
J Urol; 2016 May; 195(5):1409-1414. PubMed ID: 26707510
[TBL] [Abstract][Full Text] [Related]
24. Reducing the Harm of Prostate Cancer Screening: Repeated Prostate-Specific Antigen Testing.
Lavallée LT; Binette A; Witiuk K; Cnossen S; Mallick R; Fergusson DA; Momoli F; Morash C; Cagiannos I; Breau RH
Mayo Clin Proc; 2016 Jan; 91(1):17-22. PubMed ID: 26688045
[TBL] [Abstract][Full Text] [Related]
25. Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
Tendulkar RD; Hunter GK; Reddy CA; Stephans KL; Ciezki JP; Abdel-Wahab M; Stephenson AJ; Klein EA; Mahadevan A; Kupelian PA
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):94-9. PubMed ID: 23920389
[TBL] [Abstract][Full Text] [Related]
26. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
Carter CA; Donahue T; Sun L; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Jackmaan S; Moul JW
J Clin Oncol; 2003 Nov; 21(21):4001-8. PubMed ID: 14581423
[TBL] [Abstract][Full Text] [Related]
27. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
[TBL] [Abstract][Full Text] [Related]
28. Sociodemographic Disparities in Cure-Intended Treatment in Localized Prostate Cancer.
des Bordes JKA; Lopez DS; Swartz MD; Volk RJ
J Racial Ethn Health Disparities; 2018 Feb; 5(1):104-110. PubMed ID: 28205153
[TBL] [Abstract][Full Text] [Related]
29. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
30. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
[TBL] [Abstract][Full Text] [Related]
31. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
33. Clinical intervals and diagnostic characteristics in a cohort of prostate cancer patients in Spain: a multicentre observational study.
Bonfill X; Martinez-Zapata MJ; Vernooij RW; Sánchez MJ; Suárez-Varela MM; de la Cruz J; Emparanza JI; Ferrer M; Pijoán JI; Ramos-Goñi JM; Palou J; Schmidt S; Abraira V; Zamora J;
BMC Urol; 2015 Jul; 15():60. PubMed ID: 26134117
[TBL] [Abstract][Full Text] [Related]
34. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
[TBL] [Abstract][Full Text] [Related]
35. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the epidemiologic features and patterns of initial care for prostate cancer between public and private institutions: a survey by the Brazilian Society of Urology.
Nardi AC; Reis RB; Zequi Sde C; Nardozza A
Int Braz J Urol; 2012; 38(2):155-64; discussion 164-6. PubMed ID: 22555039
[TBL] [Abstract][Full Text] [Related]
37. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
38. US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.
Gejerman G; Ciccone P; Goldstein M; Lanteri V; Schlecker B; Sanzone J; Esposito M; Rome S; Ciccone M; Margolis E; Simon R; Guo Y; Pentakota SR; Sadeghi-Nejad H
Investig Clin Urol; 2017 Nov; 58(6):423-428. PubMed ID: 29124241
[TBL] [Abstract][Full Text] [Related]
39. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of men on active surveillance for low-risk prostate cancer at a safety-net hospital.
Osterberg EC; Palmer NRA; Harris CR; Murphy GP; Blaschko SD; Chu C; Allen IE; Cooperberg MR; Carroll PR; Breyer BN
Urol Oncol; 2017 Nov; 35(11):663.e9-663.e14. PubMed ID: 28826701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]